ArriVent BioPharma announced positive preclinical and clinical results from the FURTHER Phase 1b trial of firmonertinib for advanced EGFR PACC-mutant NSCLC. The company believes these results lay a strong foundation for its ongoing global Phase 3 ALPACCA trial.